Oncotarget: Melatonin increases overall survival of prostate cancer patients FOR IMMEDIATE RELEASE

 Oncotarget recently published "Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment" which reported that a retrospective study included 955 patients of various stages of prostate cancer who received combined hormone radiation treatment from 2000 to 2019. Comprehensive statistical methods were used to analyze the overall survival rate of PCa patients treated with melatonin in various prognosis groups.


The overall survival rate of PCa patients with favorable and intermediate prognoses treated or not treated with melatonin was not statistically significantly different.


In the poor prognosis group, the median overall survival in patients taking the drug was 153.5 months versus 64.0 months in patients not using it.


In a multivariate analysis, melatonin administration proved to be an independent prognostic factor and reduced the risk of death of PCa patients by more than twice.


The multicomponent antitumor effect of melatonin is fully realized and clearly demonstrated in treatment of PCa patients with poor prognosis with a set of unfavorable factors of the tumor progression.

Comments

Post a Comment

Popular posts from this blog

Estrogen Receptor Polymorphism Linked to Dementia in Brazilian Cohort

In an effort to learn more about dementia, researchers evaluated 178 elderly Brazilian participants in a study on estrogen receptor polymorphisms. oncotarget journal impact factor Amyloid plaques forming between neurons. Beta-amyloid protein disrupting nerve cells function in a brain with Alzheimer’s disease Listen to an audio version of this article Dementia is used as a general term to describe the age-related decline in mental capabilities that are severe enough to interfere with day-to-day activities. This disorder is multifactorial and stems from genetic, metabolic, and environmental interactions. In the elderly, Alzheimer’s disease is the most common cause of dementia. As we continue to live longer, statistics have shown that the world’s elderly population is quickly increasing. Becoming elderly often coincides with a change in lifestyle, occupation, and income—which can contribute to the onset of dementia and other chronic-degenerative diseases. The conditions that affect th
Read more

Trending with Impact: HIV Drug Repurposed to Treat Lung Cancer

Researchers based out of South Africa published a new study of a drug most commonly used to treat HIV/AIDS, efavirenz, in an initial in vitro study to treat lung cancer. Untreated human lung cancer cell A549. Untreated human lung cancer cell A549. The Trending with Impact series highlights publications attracting higher visibility among readers around the world online, in the news, and on social media — beyond normal readership levels. Look for future science news and articles about the latest trending publications here and at Oncotarget.com. — Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor drug commonly used for patients in the treatment of HIV/AIDS. Previous studies have shown that EFV also has cytotoxic effects against other cancer cells, such as colorectal, glioblastoma, and pancreatic. Researchers based out of South Africa published a new study in Oncotarget about EFV in the treatment of lung cancer and observed that numerous genes related to the cell cycle
Read more

Is Oncotarget a good journal?

Image
When general population discuss today’s medicine, precision plays one of the most crucial roles and people’s lives are directly dependent on it. Hereby, any researches related to medicine are required to meet the top standards. The problem nowadays is that any recommendations of researches can be shared online and used as a reference without being adequately checked and approved. Mikhail (Misha) Blagosklonny of Oncotarget perfectly understood this issue and decided to develop an alternative solution. That’s how a weekly oncology-focused research journal called “Oncotarget” has been established back in 2010. The main principle of this journal is related to Altmetric scores that are used as a quality indicator. That allows both readers and authors to quality-check publications with Altmetric Article Reports that provide “real-time feedback containing data summary related to a particular publication". Oncotarget website provides a complete publications list with respective scores
Read more